← All trials
NCT05273242
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 6, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Mar 10, 2022
- Last posted
- Mar 25, 2022
- Enrollment
- 400
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of NepalLead sponsor
- World Health OrganizationCollaborator
- World Health OrganizationStudy director
- Government of NepalReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.